Clinical Trials
186 trialsPazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
National Cancer Institute (NCI)
STARTRK-2
Hoffmann-La Roche
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
National Institutes of Health Clinical Center (CC)
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
PLANE-PC
University of Michigan Rogel Cancer Center
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
University of Alberta
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
ALPHAMEDIX02
Orano Med LLC
DeLLphi-307
Amgen
ANTARES
Instituto do Cancer do Estado de São Paulo
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
I-MAT
Melanoma and Skin Cancer Trials Limited
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
SUR-CAN
Centre Oscar Lambret
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
University of California, San Francisco
Entinostat Neuroendocrine (NE) Tumor
Columbia University
MOST-CIRCUIT
Olivia Newton-John Cancer Research Institute
NETTER-P
Advanced Accelerator Applications
TENET
Tata Memorial Hospital
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
University of Utah
ReLUTH
Institut du Cancer de Montpellier - Val d'Aurelle
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
Shanghai Chest Hospital
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
University of Washington
ArTisaN
Imperial College London
NELMAS
Imperial College London
PELICAN
Imperial College London
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
TaiRx, Inc.
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
Washington University School of Medicine
CapTemY90
Abramson Cancer Center at Penn Medicine
Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
University of Alberta
IMMUNORARE5
Hospices Civils de Lyon
Patients With High-grade Pancreatic Neuroendocrine Tumors
National Cancer Center, Korea
KEYNOTE 158
Merck Sharp & Dohme LLC
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
University of California, San Francisco
STOPNET
Australasian Gastro-Intestinal Trials Group
Open-Label Surufatinib in European Patients With NET
Hutchmed
TALENT
Grupo Espanol de Tumores Neuroendocrinos
LUTARTERIAL
University Hospital, Bordeaux
LUMOD-ID
University of Iowa
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh